Tibet Cheezheng Tibetan Medicine Co., Ltd. (SHE:002287)
China · Delayed Price · Currency is CNY 22.87
+0.67 (3.02%)
At close: Mar 27, 2026
SHE:002287 Revenue
In the year 2025, Tibet Cheezheng Tibetan Medicine had annual revenue of 2.42B CNY with 3.34% growth. Tibet Cheezheng Tibetan Medicine had revenue of 893.07M in the quarter ending December 31, 2025, with 3.10% growth.
Revenue
2.42B
Revenue Growth
+3.34%
P/S Ratio
5.39
Revenue / Employee
762.15K
Employees
3,170
Market Cap
13.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.42B | 78.04M | 3.34% |
| Dec 31, 2024 | 2.34B | 292.82M | 14.32% |
| Dec 31, 2023 | 2.05B | 363.07K | 0.02% |
| Jan 1, 2023 | 2.04B | 274.30M | 15.49% |
| Jan 1, 2022 | 1.77B | 285.43M | 19.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |
| Chengzhi | 11.53B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Vcanbio Cell & Gene Engineering Corp., | 1.47B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Hualan Biological Vaccine | 976.44M |
| Chengdu Olymvax Biopharmaceuticals | 704.16M |
| Mabwell (Shanghai) Bioscience | 662.52M |